Non‐adjunctive continuous glucose monitoring for control of hypoglycaemia (COACH): Results of a post‐approval observational study
Authors:
- Stayce E. BeckSBStayce E. Beck
- for the COACH Study GroupFGfor the COACH Study Group
Open Access
- 10 November 2021
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 39 (2) , e14739
Abstract
Objective: Prior to the Continuous Monitoring and Control of Hypoglycaemia (COACH) study described herein, no study had been powered to evaluate the impact of non‐adjunctive RT‐CGM use on the rate of debilitating moderate or severe hypoglycaemic events.Research Design and Methods: In this 12‐month observational study, adults with insulin‐requiring diabetes who were new to RT‐CGM participated in a 6‐month control phase where insulin dosing decisions were based on self monitoring of blood glucose values, followed by a 6‐month phase where decisions were based on RT‐CGM data (i.e. non‐adjunctive RT‐CGM use); recommendations for RT‐CGM use were made according to sites' usual care. The primary outcome was change in debilitating moderate (requiring second‐party assistance) and severe (resulting in seizures or loss of consciousness) hypoglycaemic event frequency. Secondary outcomes included changes in HbA1c and diabetic ketoacidosis (DKA) frequency.Results: A total of 519 participants with mean (SD) age 50.3 (16.1) years and baseline HbA1c 8.0% (1.4%) completed the study, of whom 32.8% had impaired hypoglycaemia awareness and 33.5% had type 2 diabetes (T2D). The mean (SE) per‐patient frequency of hypoglycaemic events decreased by 63% from 0.08 (0.016) during the SMBG phase to 0.03 (0.010) during the RT‐CGM phase (p = 0.005). HbA1c decreased during the RT‐CGM phase both for participants with type 1 diabetes (T1D) and T2D and there was a trend towards larger reductions among individuals with higher baseline HbA1c.Conclusions: Among adults with insulin‐requiring diabetes, non‐adjunctive use of RT‐CGM data is safe, resulting in significantly fewer debilitating hypoglycaemic events than management using SMBG.Keywords
Funding Information
- Dexcom
This publication has 27 references indexed in Scilit:
- Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin InjectionsJAMA, 2017
- Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin InjectionsJAMA, 2017
- Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trialThe Lancet Diabetes & Endocrinology, 2016
- FDA Advisory Panel Votes to Recommend Non-Adjunctive Use of Dexcom G5 Mobile CGMDiabetes Technology & Therapeutics, 2016
- Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: Results from the DIALOG studyDiabetes & Metabolism, 2015
- Glycemic Characteristics in Continuously Monitored Patients With Type 1 and Type 2 DiabetesDiabetes Care, 2005
- Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group.1997
- Hypoglycemia in the Diabetes Control and Complications TrialDiabetes, 1997
- Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Research and Clinical Practice, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993